The DepoVax™ and VacciMax® vaccine delivery and enhancement platforms are lipid-based formulations designed to present antigen(s) and adjuvant(s) in a unique depot with a different clearance profile than water-in-oil based vaccines. Antigens and adjuvants are encapsulated in liposomes then mixed with an oil medium to allow the targeted and controlled uptake of vaccine components by antigen presenting cells (APC’s) at the site of vaccination.  In the case of DepoVax™, a water-free formulation, Liposomes are used to bring the vaccine ingredients directly into an oil without the need for emulsification. These depot formulations are versatile and can be combined with a variety of antigens, including lysates, recombinant proteins, synthetic peptides and nucleic acids, viruses as well as a wide range of adjuvants. They have been shown to elicit potent humoral and/or cellular immunity with as little as one dose. Compared with water-in-oil emulsion-based vaccines, stronger antigen-specific IFN-γ responses and cytotoxic activity were generated. With a variety of model infectious disease antigens typically requiring multiple immunizations, strong and persistent antibody responses were generated rapidly with as little as one dose. DepoVax™ and VacciMax® are versatile platforms with the potential to significantly impact the development of human and animal health vaccines.